Cargando…

Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative

Aspergillus PCR testing of serum provides technical simplicity but with potentially reduced sensitivity compared to whole-blood testing. With diseases for which screening to exclude disease represents an optimal strategy, sensitivity is paramount. The associated analytical study confirmed that DNA c...

Descripción completa

Detalles Bibliográficos
Autores principales: White, P. Lewis, Barnes, Rosemary A., Springer, Jan, Klingspor, Lena, Cuenca-Estrella, Manuel, Morton, C. Oliver, Lagrou, Katrien, Bretagne, Stéphane, Melchers, Willem J. G., Mengoli, Carlo, Donnelly, J. Peter, Heinz, Werner J., Loeffler, Juergen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540904/
https://www.ncbi.nlm.nih.gov/pubmed/26085618
http://dx.doi.org/10.1128/JCM.00905-15
_version_ 1782386307887005696
author White, P. Lewis
Barnes, Rosemary A.
Springer, Jan
Klingspor, Lena
Cuenca-Estrella, Manuel
Morton, C. Oliver
Lagrou, Katrien
Bretagne, Stéphane
Melchers, Willem J. G.
Mengoli, Carlo
Donnelly, J. Peter
Heinz, Werner J.
Loeffler, Juergen
author_facet White, P. Lewis
Barnes, Rosemary A.
Springer, Jan
Klingspor, Lena
Cuenca-Estrella, Manuel
Morton, C. Oliver
Lagrou, Katrien
Bretagne, Stéphane
Melchers, Willem J. G.
Mengoli, Carlo
Donnelly, J. Peter
Heinz, Werner J.
Loeffler, Juergen
author_sort White, P. Lewis
collection PubMed
description Aspergillus PCR testing of serum provides technical simplicity but with potentially reduced sensitivity compared to whole-blood testing. With diseases for which screening to exclude disease represents an optimal strategy, sensitivity is paramount. The associated analytical study confirmed that DNA concentrations were greater in plasma than those in serum. The aim of the current investigation was to confirm analytical findings by comparing the performance of Aspergillus PCR testing of plasma and serum in the clinical setting. Standardized Aspergillus PCR was performed on plasma and serum samples concurrently obtained from hematology patients in a multicenter retrospective anonymous case-control study, with cases diagnosed according to European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (19 proven/probable cases and 42 controls). Clinical performance and clinical utility (time to positivity) were calculated for both kinds of samples. The sensitivity and specificity for Aspergillus PCR when testing serum were 68.4% and 76.2%, respectively, and for plasma, they were 94.7% and 83.3%, respectively. Eighty-five percent of serum and plasma PCR results were concordant. On average, plasma PCR was positive 16.8 days before diagnosis and was the earliest indicator of infection in 13 cases, combined with other biomarkers in five cases. On average, serum PCR was positive 10.8 days before diagnosis and was the earliest indicator of infection in six cases, combined with other biomarkers in three cases. These results confirm the analytical finding that the sensitivity of Aspergillus PCR using plasma is superior to that using serum. PCR positivity occurs earlier when testing plasma and provides sufficient sensitivity for the screening of invasive aspergillosis while maintaining methodological simplicity.
format Online
Article
Text
id pubmed-4540904
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-45409042015-09-22 Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative White, P. Lewis Barnes, Rosemary A. Springer, Jan Klingspor, Lena Cuenca-Estrella, Manuel Morton, C. Oliver Lagrou, Katrien Bretagne, Stéphane Melchers, Willem J. G. Mengoli, Carlo Donnelly, J. Peter Heinz, Werner J. Loeffler, Juergen J Clin Microbiol Mycology Aspergillus PCR testing of serum provides technical simplicity but with potentially reduced sensitivity compared to whole-blood testing. With diseases for which screening to exclude disease represents an optimal strategy, sensitivity is paramount. The associated analytical study confirmed that DNA concentrations were greater in plasma than those in serum. The aim of the current investigation was to confirm analytical findings by comparing the performance of Aspergillus PCR testing of plasma and serum in the clinical setting. Standardized Aspergillus PCR was performed on plasma and serum samples concurrently obtained from hematology patients in a multicenter retrospective anonymous case-control study, with cases diagnosed according to European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (19 proven/probable cases and 42 controls). Clinical performance and clinical utility (time to positivity) were calculated for both kinds of samples. The sensitivity and specificity for Aspergillus PCR when testing serum were 68.4% and 76.2%, respectively, and for plasma, they were 94.7% and 83.3%, respectively. Eighty-five percent of serum and plasma PCR results were concordant. On average, plasma PCR was positive 16.8 days before diagnosis and was the earliest indicator of infection in 13 cases, combined with other biomarkers in five cases. On average, serum PCR was positive 10.8 days before diagnosis and was the earliest indicator of infection in six cases, combined with other biomarkers in three cases. These results confirm the analytical finding that the sensitivity of Aspergillus PCR using plasma is superior to that using serum. PCR positivity occurs earlier when testing plasma and provides sufficient sensitivity for the screening of invasive aspergillosis while maintaining methodological simplicity. American Society for Microbiology 2015-08-18 2015-09 /pmc/articles/PMC4540904/ /pubmed/26085618 http://dx.doi.org/10.1128/JCM.00905-15 Text en Copyright © 2015 White et al. http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported license (http://creativecommons.org/licenses/by-nc-sa/3.0/) , which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Mycology
White, P. Lewis
Barnes, Rosemary A.
Springer, Jan
Klingspor, Lena
Cuenca-Estrella, Manuel
Morton, C. Oliver
Lagrou, Katrien
Bretagne, Stéphane
Melchers, Willem J. G.
Mengoli, Carlo
Donnelly, J. Peter
Heinz, Werner J.
Loeffler, Juergen
Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative
title Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative
title_full Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative
title_fullStr Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative
title_full_unstemmed Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative
title_short Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative
title_sort clinical performance of aspergillus pcr for testing serum and plasma: a study by the european aspergillus pcr initiative
topic Mycology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540904/
https://www.ncbi.nlm.nih.gov/pubmed/26085618
http://dx.doi.org/10.1128/JCM.00905-15
work_keys_str_mv AT whiteplewis clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT barnesrosemarya clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT springerjan clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT klingsporlena clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT cuencaestrellamanuel clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT mortoncoliver clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT lagroukatrien clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT bretagnestephane clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT melcherswillemjg clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT mengolicarlo clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT donnellyjpeter clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT heinzwernerj clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative
AT loefflerjuergen clinicalperformanceofaspergilluspcrfortestingserumandplasmaastudybytheeuropeanaspergilluspcrinitiative